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Purpose of the study
In the post-HAART era, the incidence of minor cognitive
and motor deficits (MCMD) in HIV-1 infected subjects
has increased. A rapid and sensitive screening tool to iden-
tify individuals with HIV-associated neurocognitive
impairment (NCI) is needed to determine how best to
prevent and treat these conditions. This study aimed to
determine whether the Prospective & Retrospective Mem-
ory Questionnaire (PRMQ) could be a useful screening
tool for HIV-associated NCI, by comparing with indices of
a brief computerised battery test.
Methods
The PRMQ and a computerised battery test with a high
positive predictive value for detecting HIV-associated NCI
(CogState™) were administered to HIV-positive patients
stable on HAART. Selection inclusion criteria included
plasma HIV-RNA level <50 copies/mL for a minimum of
3 months. Cerebral impairment was defined as either
memory impairment (MI, a Z score of more than two SD
from the sample mean for PRMQ) or NCI, a Z-score of
more than two SD in more than two tasks on the compu-
terised battery test. SPSS software was used for analysis.
Summary of results
Forty-five patients were recruited between March and
April 2008; 80% were male. Mean age was 48 years (SD
11.2) and mean CD4 count was 546 cells/uL (range 70–
1,350). 31% and 69% were taking NNRTI and PI-based
HAART, respectively. Seven subjects were identified with
cerebral impairment; NCI in five (11.1%) and MI in two
(4.4%). No subjects had both MI and NCI as defined by
study tests. PRMQ scores were compared to population
data (n = 551) and MI was also identified in the same two
subjects. No statistically significant correlations were
observed between total PRMQ score and global (average)
computer score (p > 0.05) or between type of ARV therapy
(NNRTI vs. PI) and either total score (p => 0.05). How-
ever, on analysis of specific domains, the PRMQ 'short
term memory' section significantly correlated with both
overall global score (r = -0.31, p < 0.05) and "memory &
learning" domain of the computerised battery (r = -0.36,
p < 0.05).
Conclusion
The PRMQ is not a good screening tool for NCI in HIV-1
infected subjects. However, the PRMQ did demonstrate
correlation between identification of memory and learn-
ing deficits, when compared to the computerised battery
test, and identified individuals with MI at similar rates to
population data. We may thus be observing two distinct
processes; HIV-related NCI and early stages of cortical
memory loss with both tools having different utilities in
future clinical practice.
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